Alaunos Therapeutics, Inc.
TCRT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.03 | 0.07 | 0.65 |
| FCF Yield | -162.54% | -178.77% | -20.89% | -27.72% |
| EV / EBITDA | -0.42 | -0.35 | -3.83 | -2.50 |
| Quality | ||||
| ROIC | -233.25% | -543.32% | -59.85% | -87.97% |
| Gross Margin | 100.00% | -95,960.00% | 5.58% | -85.93% |
| Cash Conversion Ratio | 1.06 | 0.86 | 0.77 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | -84.93% | -76.75% | – | – |
| Free Cash Flow Growth | 83.62% | -3.03% | 54.55% | 2.99% |
| Safety | ||||
| Net Debt / EBITDA | 0.23 | 0.20 | 0.60 | 0.61 |
| Interest Coverage | 0.00 | -17.84 | -11.13 | -65.61 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.20 | 0.00 |
| Cash Conversion Cycle | 182.50 | 26.19 | 1,660.66 | 344.13 |